Your browser doesn't support javascript.
Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review.
Safety and Risk of Pharmacotherapy ; 10(4):326-344, 2022.
Artículo en Ruso | EMBASE | ID: covidwho-20238190
ABSTRACT
The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential adverse drug reactions (ADRs) and their predictors in etiology- and pathogenesis-oriented COVID-19 therapy. According to literature data, the main clinically significant risk factors for COVID-19 patients to develop an ADR are the duration of their hospital stay, combined use of antivirals, polypharmacy, and their history of drug allergies. The most common adverse reactions to antivirals, to virus-neutralising antibodies, and to human anti-COVID-19 immunoglobulin and convalescent plasma are, respectively, gastrointestinal and hepatobiliary disorders;gastrointestinal disorders, neurological disorders, and allergic reactions;and transfusion reactions (fever, chills, etc.). For pathogenesis-oriented therapy with systemic glucocorticosteroids, the most characteristic ADR is hyperglycaemia. Janus kinase inhibitors and interleukin inhibitors are most often associated with gastrointestinal disorders and hypertransaminasemia;neutropenia is also characteristic of a number of interleukin inhibitors. Haemostatic adverse reactions to anticoagulants depend on the patient's dosing regimen and condition. Drug-drug interactions are a common problem in COVID-19 treatment, with the combination of nirmatrelvir and ritonavir showing the largest number of significant interactions attributed to their pharmacokinetics. Currently, there is data on the role of pharmacogenetic biomarkers in the safety and clinical outcomes of COVID-19 therapy. Thus, to improve the safety of COVID-19 therapy, an integrated approach is needed that will take into account both the clinical, demographic, and pharmacogenetic predictors of ADRs and the risk of drug-drug interactions.Copyright © 2023 Safety and Risk of Pharmacotherapy. All rights reserved.
Palabras clave
adverse drug reactions; covid-19; drug-drug interactions; interleukin inhibitors; monoclonal antibodies; nirmatrelvir+ritonavir; pharmacogenetics; pharmacovigilance; allergy/si [Side Effect]; chill/si [Side Effect]; clinical outcome; combination drug therapy; coronavirus disease 2019/dt [Drug Therapy]; demography; drug interaction; drug safety; fever/si [Side Effect]; gastrointestinal disease/si [Side Effect]; hematologic disease/si [Side Effect]; hepatobiliary disease/si [Side Effect]; hospitalization; human; hyperglycemia/si [Side Effect]; hypertransaminasemia/si [Side Effect]; length of stay; medical history; neurologic disease/si [Side Effect]; neutropenia/si [Side Effect]; outcome assessment; pathogenesis; pharmacokinetic parameters; polypharmacy; review; risk assessment; risk factor; side effect/si [Side Effect]; anticoagulant agent/ae [Adverse Drug Reaction]; anticoagulant agent/dt [Drug Therapy]; antivirus agent/ae [Adverse Drug Reaction]; antivirus agent/dt [Drug Therapy]; biological marker/ec [Endogenous Compound]; convalescent plasma; cytokine receptor antagonist/ae [Adverse Drug Reaction]; cytokine receptor antagonist/dt [Drug Therapy]; glucocorticoid/ae [Adverse Drug Reaction]; glucocorticoid/dt [Drug Therapy]; immunoglobulin/ae [Adverse Drug Reaction]; immunoglobulin/dt [Drug Therapy]; Janus kinase inhibitor/ae [Adverse Drug Reaction]; Janus kinase inhibitor/dt [Drug Therapy]; neutralizing antibody/ae [Adverse Drug Reaction]; neutralizing antibody/dt [Drug Therapy]; nirmatrelvir/ae [Adverse Drug Reaction]; nirmatrelvir/dt [Drug Therapy]; ritonavir/ae [Adverse Drug Reaction]; ritonavir/dt [Drug Therapy]

Texto completo: Disponible Colección: Bases de datos de organismos internacionales Base de datos: EMBASE Tipo de estudio: Estudio de etiologia / Estudio pronóstico / Revisiones Idioma: Ruso Revista: Safety and Risk of Pharmacotherapy Año: 2022 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos de organismos internacionales Base de datos: EMBASE Tipo de estudio: Estudio de etiologia / Estudio pronóstico / Revisiones Idioma: Ruso Revista: Safety and Risk of Pharmacotherapy Año: 2022 Tipo del documento: Artículo